Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study

Bipolar Disorders

Volumn 18, Issue 8, 2016, Pages 684-691

  Hochman, Eldar ^a,b   Krivoy, Amir ^a,b   Schaffer, Ayal ^c,d   Weizman, Abraham ^a,b   Valevski, Avi ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

atypical antipsychotics; bipolar disorder; lithium; manic episode; rehospitalization; typical antipsychotics; valproate

Indexed keywords

AMISULPRIDE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROIC ACID; ZUCLOPENTHIXOL; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; AFFECT; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; ISRAEL; PROCEDURES; PSYCHOLOGY; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AFFECT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISRAEL; LITHIUM; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT READMISSION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; VALPROIC ACID;

EID: 85006390569     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12459     Document Type: Article

References (25)

1. Kendall T, Morriss R, Mayo-Wilson E, Marcus E. Guideline Development Group of the National Institute for Health and Care Excellence. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349:g5673.
2. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2013;14:154–219.
3. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217–222.
4. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord. 2008;110:135–141.
5. Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry. 2011;11:171.
6. Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22:825–835.
7. Vieta E, Reinares M, Corbella B, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001;21:469–473.
8. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109:251–263.
9. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013;147:365–372.
10. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry J Ment Sci. 2004;184:337–345.
11. Carlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord. 2012;14:41–53.
12. Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review J Affect Disord. 2014;152–154:12–18.
13. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DPJ. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry Off J World Psychiatr Assoc WPA. 2016;15:53–58.
14. Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry. 2016;21:1050–1056.
15. Sokolski KN, Denson TF. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:863–866.
16. Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res. 2005;32:438–445.
17. Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol. 1986;1(Suppl 1):53–62.
18. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry J Ment Sci. 1986;148:723–725.
19. Goikolea JM, Colom F, Torres I, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord. 2013;144:191–198.
20. Woo YS, Bahk W-M, Jung Y-E, et al. One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics. Psychiatry Clin Neurosci. 2014;68:418–424.
21. Lin C-H, Huang C-W, Chen C-C, Hsu Y-F, Chang W-H, Lane H-Y. Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics. Psychopharmacology. 2008;200:301–303.
22. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994–1999. Br J Psychiatry J Ment Sci. 2004;185:372–377.
23. Zis AP, Grof P, Webster M, Goodwin FK. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull. 1980;16:47–49.
24. Kessing LV. Recurrence in affective disorder. II. Effect of age and gender. Br J Psychiatry J Ment Sci. 1998;172:29–34.
25. Reinares M, Papachristou E, Harvey P, et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. J Affect Disord. 2013;144:65–71.